Your browser is no longer supported. Please, upgrade your browser.
Settings
CLLS Cellectis S.A. daily Stock Chart
CLLS [NASD]
Cellectis S.A.
Index- P/E- EPS (ttm)-1.62 Insider Own- Shs Outstand42.86M Perf Week-5.87%
Market Cap652.76M Forward P/E- EPS next Y-2.31 Insider Trans- Shs Float31.64M Perf Month2.35%
Income- PEG- EPS next Q-0.60 Inst Own31.10% Short Float1.05% Perf Quarter-24.19%
Sales16.80M P/S38.86 EPS this Y30.70% Inst Trans-0.06% Short Ratio3.03 Perf Half Y-9.18%
Book/sh9.22 P/B1.65 EPS next Y-5.00% ROA- Target Price41.90 Perf Year-50.23%
Cash/sh- P/C- EPS next 5Y- ROE- 52W Range13.84 - 30.68 Perf YTD-8.53%
Dividend- P/FCF- EPS past 5Y-21.20% ROI-25.60% 52W High-50.36% Beta1.73
Dividend %- Quick Ratio9.70 Sales past 5Y11.00% Gross Margin- 52W Low10.04% ATR0.52
Employees149 Current Ratio9.80 Sales Q/Q-58.00% Oper. Margin- RSI (14)40.24 Volatility2.12% 3.21%
OptionableYes Debt/Eq0.09 EPS Q/Q39.70% Profit Margin- Rel Volume0.47 Prev Close15.25
ShortableYes LT Debt/Eq0.08 EarningsAug 06 BMO Payout- Avg Volume109.72K Price15.23
Recom1.80 SMA20-2.60% SMA50-6.94% SMA200-21.36% Volume52,092 Change-0.13%
May-24-19Resumed Citigroup Neutral $22
Mar-14-19Initiated William Blair Outperform
Dec-19-18Initiated Goldman Neutral
Jul-16-18Initiated Barclays Overweight $50
Mar-16-18Initiated Guggenheim Neutral
Sep-05-17Reiterated Wells Fargo Outperform $33 → $40
Sep-05-17Downgrade SunTrust Buy → Hold
Mar-02-17Initiated Instinet Buy $49
Feb-28-17Initiated Wells Fargo Outperform
Apr-05-16Initiated Ladenburg Thalmann Buy $45
Mar-02-16Initiated Sun Trust Rbsn Humphrey Buy
Jul-20-15Initiated BofA/Merrill Buy $50
Apr-20-15Initiated Piper Jaffray Overweight $42
Apr-20-15Initiated Jefferies Buy $46
Jul-08-19 04:30PM  Cellectis Publishes New CAR Design to Control CAR T-Cells in Non-Lethal Way Business Wire
Jun-26-19 04:30PM  Cellectis S.A. Reports Results from Combined Shareholders Meeting Held on June 25, 2019 Business Wire
May-07-19 04:32PM  Cellectis Reports Financial Results for First Quarter 2019 Business Wire
Apr-17-19 04:30PM  Cellectis Announces Oral and Poster Presentations of Allogeneic CAR T-Cell Programs at the 2019 ASGCT Annual Meeting Business Wire
Apr-03-19 08:19AM  The Daily Biotech Pulse: Advaxis Offering, Roche's Spark Tender Offer Extended, Ascendis Earnings Benzinga
Apr-02-19 04:30PM  FDA Clears the IND for UCARTCS1, the First Allogeneic CAR-T to Treat Multiple Myeloma Patients Business Wire
Mar-11-19 04:10PM  Cellectis Reports 4th Quarter and Full Year 2018 Financial Results Business Wire
Mar-07-19 04:30PM  Cellectis Enters Lease Agreement to Build Manufacturing Facility, Advancing Towards Commercialization of its UCART Portfolio Business Wire
02:47PM  5 Top Gene-Editing Stocks for 2019 Motley Fool
Feb-25-19 05:10PM  Cellectis Publishes Novel Methods to Improve the Safety of CAR T-Cell Therapy and Prevent CRS in the Journal of Biological Chemistry Business Wire
Feb-07-19 07:25AM  Consolidated Research: 2019 Summary Expectations for Oceaneering International, Southwest Gas, WellCare Health Plans, Barnes & Noble, Cellectis S.A, and Payment Data Fundamental Analysis, Key Performance Indications GlobeNewswire
Dec-10-18 04:30PM  Cellectis Appoints William Monteith as Senior Vice President U.S. Manufacturing Business Wire
Nov-13-18 04:30PM  Cellectis Reports Financial Results for 3rd Quarter and First Nine Months 2018 Business Wire
Oct-17-18 08:10AM  New Research Coverage Highlights Esperion Therapeutics, Summit Therapeutics, Ocwen Financial, Keane Group, Cellectis S.A, and Rapid7 Consolidated Revenues, Company Growth, and Expectations for 2018 GlobeNewswire
Sep-19-18 04:30PM  CAR-T Pioneer Dr. Stephan A. Grupp to Join Cellectis Clinical Advisory Board Business Wire
Sep-18-18 04:30PM  Calyxt Appoints CEO, Jim Blome, Former President & CEO of Bayer CropScience LP Business Wire
Aug-20-18 07:40AM  Report: Exploring Fundamental Drivers Behind Ballard Power, Reading International, Odonate Therapeutics, Stitch Fix, Summit Therapeutics, and Cellectis S.A New Horizons, Emerging Trends, and Upcoming Developments GlobeNewswire
Aug-02-18 04:30PM  Cellectis Appoints Stefan Scherer M.D., Ph.D., as Senior Vice President Clinical Development and Deputy Chief Medical Officer Business Wire
Aug-01-18 04:30PM  Cellectis Reports Financial Results for 2nd Quarter and First Six Months 2018 Business Wire
Jun-27-18 04:30PM  Cellectis S.A. Reports Results from Annual General Meeting Held on June 26, 2018 Business Wire
Jun-12-18 04:30PM  Cellectis Publishes Novel Methods to Improve the Clinical Use of Chimeric Antigen Receptor T-Cell Therapy in Scientific Reports Business Wire
Jun-08-18 09:56AM  Should Cellectis SA.s (NASDAQ:CLLS) Recent Earnings Decline Worry You? Simply Wall St.
Jun-05-18 07:35AM  Detailed Research: Economic Perspectives on Galapagos NV, Cellectis S.A, MediciNova, Logitech International S.A, The Descartes Systems Group, and Canadian Pacific Railway What Drives Growth in Today's Competitive Landscape GlobeNewswire
Jun-04-18 04:30PM  FDA Grants Cellectis IND Approval for UCART22 in B-ALL Business Wire
May-22-18 07:59PM  INSERTING and REPLACING: Approval of UCART123 Amendment in AML to Accelerate Clinical Development Business Wire
04:30PM  Cellectis: Approval of UCART123 Amendment in AML to Accelerate Clinical Development Business Wire
May-21-18 08:30AM  Cellectis S.A.: Calyxt Announces Full Exercise of Underwriters Option to Purchase Additional Shares Business Wire
May-15-18 05:50PM  Calyxt Announces Launch of Proposed Follow-On Offering Business Wire
May-10-18 05:15PM  Cellectis to Present Data at the 2018 ASGCT Annual Meeting Business Wire
07:30AM  Wired News - Atara Biotherapeutics Expands T-Cell Immunotherapy Collaboration with MSK to Develop Next-Generation CAR T Technologies ACCESSWIRE
May-07-18 04:30PM  Cellectis Reports 1st Quarter 2018 Financial Results Business Wire
May-02-18 04:30PM  Cellectis Files IND for UCART22 in Acute Lymphoblastic Leukemia (B-ALL) Business Wire
May-01-18 07:01AM  George Church, CRISPR Pioneer, Embraces Alternative Tech In Project To Recode A Human Genome Forbes
07:00AM  Harvards Wyss Institute Partners with Cellectis to Recode the Human Genome Business Wire
Apr-18-18 01:37AM  Should Cellectis SA.s (EPA:ALCLS) Recent Earnings Decline Worry You? Simply Wall St.
Apr-13-18 08:15AM  What Should We Expect From Cellectis SA.s (NASDAQ:CLLS) Earnings Over The Next Few Years? Simply Wall St.
Apr-11-18 07:40AM  Consolidated Research: 2018 Summary Expectations for Ctrip.com International, JA Solar Holdings, Co., Oaktree Specialty Lending, Rhythm Pharmaceuticals, Cellectis S.A, and Travelport Worldwide Fundamental Analysis, Key Performance Indications GlobeNewswire
01:50AM  Cellectis to Present Data at the 2018 AACR Annual Meeting Business Wire
Apr-10-18 04:10PM  Cellectis Announces Closing of Follow-On Offering Business Wire
Apr-07-18 08:34AM  Is Cellectis SA Stock a Buy Now? Motley Fool
Apr-06-18 08:45AM  Can Been-There Biotech Entrepreneur Arie Belldegrun Do It Yet Again? Motley Fool
Apr-05-18 04:34PM  Why Micron Technology, Mechel, and Cellectis Slumped Today Motley Fool -12.39%
08:05AM  Could Orgenesis (ORGS) be the Next Acquisition Target in Cell Therapy Space? ACCESSWIRE
Apr-04-18 08:30PM  Cellectis Announces Pricing of Follow-On Offering Business Wire -14.09%
Apr-03-18 05:45PM  Cellectis Announces Launch of Follow-On Offering Business Wire +25.38%
04:09PM  Pfizer Takes On Gilead, Novartis With New Deal In Cancer Drugs Investor's Business Daily
01:14PM  Pfizer in deal with Allogene to develop cancer cell therapies Reuters
08:10AM  Cellectis and Allogene Therapeutics Intend to Continue Strategic Cancer Immunotherapy Collaboration to Accelerate Development and Commercialization of Allogeneic Off-the-Shelf CAR T Therapies Business Wire
Mar-19-18 03:06AM  What Should Investors Know About Cellectis SA.s (EPA:ALCLS) Earnings Trend? Simply Wall St.
Mar-16-18 02:33PM  The Week Ahead In Biotech: Earnings, PDUFA Dates And More Benzinga
Mar-15-18 08:10AM  Report: Exploring Fundamental Drivers Behind Mountain Province Diamonds, Limoneira, Arsanis, ExlService, Argo Group International, and Cellectis S.A. New Horizons, Emerging Trends, and Upcoming Developments GlobeNewswire
Mar-13-18 04:30PM  Dr. Mathieu Simon to Retire as Cellectis Chief Operating Officer; Elsy Boglioli Named as Successor Business Wire
08:22AM  Cellectis SA.s (NASDAQ:CLLS) Profit Outlook Simply Wall St.
Mar-12-18 04:51PM  Cellectis Reports 4th Quarter and Full Year 2017 Financial Results Business Wire
Mar-08-18 04:30PM  Cellectis: Servier and Pfizer Announce Results of UCART19 First-in-Human Trials to Be Presented at the 44th EBMT (European Society for Blood and Marrow Transplantation) Annual Meeting Business Wire
Mar-05-18 12:00AM  [$$] Crispr gene editing ready for testing in humans Financial Times
Feb-13-18 12:01AM  Two Issued U.S. Patents Granted to Cellectis for CRISPR Use in T-Cells Business Wire
12:00AM  France's Cellectis wins U.S patents for gene editing technology Reuters
Jan-02-18 04:30PM  Cellectis to Present at the 36th Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2018 at 12:00 P.M. PT Business Wire
Dec-26-17 11:22AM  ETFs with exposure to Cellectis SA : December 26, 2017 Capital Cube
Dec-25-17 09:37AM  Cellectis SA :CLLS-US: Earnings Analysis: Q3, 2017 By the Numbers : December 25, 2017 Capital Cube
Dec-14-17 10:28AM  Company News For Dec 14, 2017 Zacks
Dec-13-17 04:07PM  This Biotech Stock Rocketed On Human Trials For New Cancer Drug Investor's Business Daily +11.57%
11:05AM  Why Cellectis Is Winning Big With Its Pfizer Partnership 24/7 Wall St.
Dec-12-17 06:38PM  Preliminary Data from Servier and Pfizers UCART19 Product Candidate Shows High Complete Remission Rate Across Two Phase I Adult and Pediatric Acute Lymphoblastic Leukemia Trials Business Wire
Dec-04-17 04:30PM  Cellectis Appoints Immuno-Oncology Leader Stéphane Depil to Position of Senior Vice President Research & Development and Chief Medical Officer Business Wire
04:30PM  Cellectis Appoints Elsy Boglioli to Executive Vice President, Strategy and Corporate Development Business Wire
Nov-30-17 07:40AM  Blog Exposure - Viking Therapeutics Reports Positive Top-Line Results from Phase-2 Study of VK5211 in Patients Recovering from Hip Fracture ACCESSWIRE
Nov-20-17 04:30PM  Cellectis Demonstrates Fine and Predictable Tuning of TALEN® Gene Editing Targeting to Improve T-cell Adoptive Immunotherapy Business Wire
Nov-15-17 11:42AM  ETFs with exposure to Cellectis SA : November 15, 2017 Capital Cube
Nov-14-17 07:00AM  Cellectis SA to Host Earnings Call ACCESSWIRE
Nov-13-17 04:15PM  Cellectis Reports Financial Results for Third Quarter and First Nine Months of 2017 Business Wire
Nov-09-17 08:28AM  Biotech Stock Roundup: Regeneron Delivers Strong Q3 Results, Cellectis Clinical Hold Lifted Zacks
Nov-06-17 07:00PM  FDA Lifts Clinical Hold on Cellectis Phase 1 Clinical Trials with UCART123 in AML and BPDCN Business Wire
Nov-03-17 12:03PM  ETFs with exposure to Cellectis SA : November 3, 2017 Capital Cube
Nov-01-17 04:15PM  Servier and Pfizer Announce Preliminary Results of the First-in-Human Trials of UCART19 Will Be Presented at the 59th American Society of Hematology (ASH) Annual Meeting Business Wire -16.65%
04:15PM  Cellectis Announces Two Oral Presentations and One Poster Presentation at the 2017 ASH Annual Meeting Business Wire
Oct-24-17 09:36AM  ETFs with exposure to Cellectis SA : October 24, 2017 Capital Cube
Oct-13-17 10:38AM  ETFs with exposure to Cellectis SA : October 13, 2017 Capital Cube
Oct-04-17 04:30PM  Mathieu Simon, M.D. Cellectis EVP & Chief Operating Officer, to Serve as Interim Chief Medical Officer Business Wire
Oct-02-17 03:56PM  Bluebird Bio: So Much for That Gilead Boost Barrons.com
Sep-29-17 09:04AM  Cellectis SA :CLLS-US: Earnings Analysis: Q2, 2017 By the Numbers : September 29, 2017 Capital Cube
Sep-27-17 06:54AM  Juno Therapeutics Inc (JUNO): 3 Reasons to Be Bullish InvestorPlace
Sep-08-17 01:43PM  INVESTOR ALERT: Goldberg Law PC Announces an Investigation of Cellectis S.A. Business Wire +6.12%
Sep-07-17 03:29PM  INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of Cellectis S.A. Business Wire
Sep-06-17 08:29AM  Biotech Stock Roundup: Cellectis Down on Clinical Hold, Insmed Soars on Positive Data Zacks
Sep-05-17 05:16PM  SHAREHOLDER ALERT: Goldberg Law PC Announces an Investigation of Cellectis S.A. Business Wire -20.26%
04:47PM  Why Mallinckrodt, Universal Insurance Holdings, and Cellectis Slumped Today Motley Fool
03:45PM  SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of Cellectis S.A. Business Wire
02:18PM  SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Cellectis S.A. (CLLS) PR Newswire
02:15PM  Here's Why Cellectis SA Fell as Much as 31.6% Today Motley Fool
12:17PM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cellectis S.A. - CLLS PR Newswire
08:46AM  Cellectis's stock plunges after leukemia treatment trials were put on hold MarketWatch
Sep-04-17 10:30PM  Cellectis to Participate in Upcoming Investor Conferences Business Wire
10:13PM  Cellectis Reports Clinical Hold of UCART123 Studies Business Wire
Aug-29-17 08:40AM  Cellectis (CLLS) Catches Eye: Stock Jumps 17% Zacks
Aug-28-17 11:41AM  Biotech stocks surge on Gilead's Kite Pharma acquisition MarketWatch +17.03%
Aug-17-17 04:30PM  Cellectis UCART123 Administered to First Patient with BPDCN in Phase I Clinical Trial at MD Anderson Cancer Center Business Wire
Aug-02-17 04:30PM  Cellectis Reports Financial Results for 2nd Quarter and First Six Months 2017 Business Wire
Jul-25-17 04:01PM  Cellectis S.A.: Calyxt Announces Full Exercise of Over-Allotment Option and Closing of its Initial Public Offering Business Wire
Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia (ALL); UCART22 to treat ALL and non-Hodgkin lymphoma (NHL); ALLO-501 for treating relapsed/refractory NHL; and UCART123 for the treatment of acute myeloid leukemia (AML) and blastic plasmacytoid dendritic cell neoplasm. It is also developing UCARTCLL1 to treat AML; ALLO-819 for treating AML; UCARTCS1 for the treatment of multiple myeloma (MM); and ALLO-715 to treat MM. In addition, the company produces high oleic soybean oil, other soybean products, and fiber wheat. It has strategic alliances with Allogene Therapeutics, Inc.; Les Laboratoires Servier; The University of Texas M.D. Anderson Cancer Center; Cornell University; Dana Farber Cancer Institute; and H. Lee Moffitt Cancer Center. Cellectis S.A. was founded in 1999 and is based in Paris, France.